FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD

MARLBOROUGH, Mass.--(BUSINESS WIRE) August 31, 2018 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the New Drug Application (NDA) for dasotraline, a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news